This Phase 1b study will evaluate the safety of PRV-3279 in healthy adult subjects
PRV-3279-1b is a Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects. Eligible subjects include healthy male or female adults, 18 to 50 years of age. Each subject will receive the assigned treatment over 29 days followed by a 56-day follow-up period.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
16
bi-specific antibody-based molecule
Clinical site
Baltimore, Maryland, United States
Incidence and severity of treatment-emergent adverse events (TEAEs)
Assessment of safety and tolerability
Time frame: 85 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.